Browse News
Filter News
Found 251 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Xcell Biosciences Announces New Scientific and Business Advisory Board
3/27/2024
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
-
CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)
3/19/2024
CHARM Therapeutics Announces Foundation of Scientific Advisory Board.
-
If you’re a life sciences professional in the Genetown hotbed (Boston, Cambridge and the surrounding areas of Massachusetts) and are looking for your next challenge, take a look at these companies hiring on BioSpace.
-
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2/29/2024
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023.
-
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
2/28/2024
Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024.
-
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
2/16/2024
Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.
-
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
2/13/2024
Sana Biotechnology, Inc. announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.”
-
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/12/2024
Sana Biotechnology, Inc. announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share.
-
Sana Biotechnology Announces Pricing of Upsized Public Offering - February 08, 2024
2/8/2024
Sana Biotechnology, Inc. announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share.
-
Sana Biotechnology Announces Proposed Public Offering of Common Stock - February 07, 2024
2/7/2024
Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
1/8/2024
Flagship Pioneering, the bioplatform innovation company, and Samsung announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.
-
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
1/5/2024
Sail Biomedicines, Inc. today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.
-
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
1/5/2024
Sana Biotechnology, Inc. announced the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy.
-
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024.
-
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
12/11/2023
Sana Biotechnology, Inc. (NASDAQ: SANA) today announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology were presented at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
-
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
12/1/2023
Sana Biotechnology, Inc. (NASDAQ: SANA) today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy.
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
11/28/2023
Thermo Fisher Scientific Inc., the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis.
-
Sana Biotechnology to Present at November and December 2023 Investor Conferences
11/21/2023
Sana Biotechnology, Inc. today announced that it will webcast its presentations at two investor conferences in November and December.
-
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
11/17/2023
Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.